View More Recent Stories

May 2, 2018 04:10PM Humanigen Announces Preclinical Findings Presented on Lenzilumab’s Potential to Optimize CAR-T Therapy
Apr 30, 2018 07:00AM Humanigen Names Dr. Tarek Sahmoud as Chief Medical Officer
Apr 30, 2018 07:00AM Humanigen Names Dr. Tarek Sahmoud as Chief Medical Officer
Apr 16, 2018 07:00AM Humanigen Signs Agreement With MD Anderson Cancer Center to Begin Research Investigating Lenzilumab as CAR-T Support
Apr 16, 2018 07:00AM Humanigen Signs Agreement With MD Anderson Cancer Center to Begin Research Investigating Lenzilumab as CAR-T Support
Mar 15, 2018 07:00AM Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
Mar 15, 2018 07:00AM Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
Mar 1, 2018 04:50PM Form SC 13D/A HUMANIGEN, INC Filed by: BLACK HORSE CAPITAL LP
Feb 27, 2018 04:05PM Humanigen Completes Exchange of Loan Obligations for Equity
Feb 27, 2018 04:05PM Humanigen Completes Exchange of Loan Obligations for Equity
Jan 26, 2018 05:16PM Form SC 13D/A HUMANIGEN, INC Filed by: BLACK HORSE CAPITAL LP
Dec 21, 2017 04:45PM Humanigen Signs Definitive Agreements to Exchange Loan Obligations for Equity
Dec 21, 2017 04:45PM Humanigen Signs Definitive Agreements to Exchange Loan Obligations for Equity
Jul 11, 2016 06:33PM Form 3 KALOBIOS PHARMACEUTICALS For: Jun 30 Filed by: BLACK HORSE CAPITAL LP
Jul 11, 2016 05:17PM Form SC 13D KALOBIOS PHARMACEUTICALS Filed by: BLACK HORSE CAPITAL LP
Jul 1, 2016 07:03AM KaloBios (KBIOQ) Completes Chapter 11 Bankruptcy; Acquires Benznidazole Development Rights
Jul 1, 2016 07:00AM KaloBios Emerges from Chapter 11 Bankruptcy
View More Recent Stories